Native™ Antibody Discovery

Tests for immunoglobulin reactivity with specific antigens are some of the most conventional assays in antibody discovery. Creative Biolabs has proudly developed the antigen-specific B lymphocytes cytometry technology to discovering native monoclonal antibodies.

Although in vitro antibody display is widely used currently, it cannot provide antibodies with naturally paired heavy chain (VH) and light chain (VL). For the construction of random pairing of VH and VL in synthesis or naïve antibody libraries, the natural or synthetic pairings of heavy and light chains are constructed as combinatorial libraries. The random antibody construction could potentially lead to the generation of antibody molecules that have suboptimal solubility or other unsatisfied biophysical characteristics. Antibodies derived from these technologies most likely do not represent the naturally cognate heavy and light chains.

Other limitation of in vitro antibody display is that antibodies derived from in vitro display methods generally do not have enough affinity to the targets (often in the 1-50 nM K_D range). Therefore, affinity maturation is required for therapeutic usage.

To overcome the limitations of in vitro display for antibody discovery, Creative Biolabs has developed the exclusive Native™ Antibody Discovery Platform to isolate single antigen specific plasma cells. By this platform, we can help you find Native™ antibodies with extremely high in vivo specificity and affinity. Moreover, this novel technology allows us to select a large number of antibody candidates simultaneously, which saving a lot of time and energy. The selection only takes 2-3 weeks after immunization. It should be considered by far the most efficient way in developing native monoclonal antibodies.

Benefits of our Native™ Antibody Discovery Service including but not limited to:

• A wide selection of species: Native™ Antibody Discovery has diverse nature, any immunized animals or vaccinated humans can be analyzed for monoclonal antibody development. The species include humans, rabbits, rats, mice, chicken and other species such as camelids, sheep, monkeys, dogs, cows, etc.
• High affinity: As the antibodies are derived from terminally differentiated plasma cells, they have already gone through natural selection to form native pairs of HC and LC with high affinity.
• High specificity and stability in vivo.
• Large pool of antibody candidates.
• Competitive and affordable price.
• Short timeline: The advances of Native™ Antibody Discovery Technology shorten the monoclonal antibody development timeline from 4 months to 2-3 weeks.

For more detailed information, please feel free to contact us or directly sent us an inquiry .

For Research Use Only.